Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Sai Life Sciences IPO is a book build issue of ₹3,042.62 crores. The issue is a combination of fresh issue of 1.73 crore shares aggregating to ₹950.00 crores and offer for sale of 3.81 crore shares aggregating to ₹2,092.62 crores.
Sai Life Sciences IPO bidding started from Dec 11, 2024 and ended on Dec 13, 2024. The allotment for Sai Life Sciences IPO was finalized on Dec 16, 2024. The shares got listed on BSE, NSE on Dec 18, 2024.
Sai Life Sciences IPO price band is set at ₹549.00 per share . The lot size for an application is 27. The minimum amount of investment required by an retail is ₹14,094 (27 shares). The lot size investment for sNII is 14 lots (378 shares), amounting to ₹2,07,522, and for bNII, it is 68 lots (1,836 shares), amounting to ₹10,07,964.
Kotak Mahindra Capital Co.Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Refer to Sai Life Sciences IPO RHP for detailed Information.
| IPO Date | December 11, 2024 to December 13, 2024 |
| Listing Date | December 18, 2024 |
| Face Value | ₹1 per share |
| Issue Price Band | ₹522 to ₹549 per share |
| Issue Price Final | ₹549 per share |
| Lot Size | 27 Shares |
| Sale Type | Fresh Capital-cum-Offer for Sale |
| Total Issue Size | 5,54,21,123 shares (aggregating up to ₹3,042.62 Cr) |
| Fresh Issue | 1,73,04,189 shares (aggregating up to ₹950.00 Cr) |
| Offer for Sale | 3,81,16,934 shares of ₹1 (aggregating up to ₹2,092.62 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 19,06,85,340 shares |
| Share Holding Post Issue | 20,79,89,529 shares |
Sai Life Sciences IPO offers total 5,54,21,123 shares. Out of which 2,77,10,560 (50.00%) allocated to QIB, 1,10,84,224 (20.00%) allocated to QIB, 83,13,169 (15.00%) allocated to NII, 1,93,97,394 (35.00%) allocated to RII and 1,66,26,336 (30.00%) allocated to Anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 2,77,10,560 (50.00%) | NA |
| − Anchor Investor Shares Offered | 1,66,26,336 (30.00%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 1,10,84,224 (20.00%) | NA |
| NII (HNI) Shares Offered | 83,13,169 (15.00%) | NA |
| − bNII > ₹10L | 55,42,113 (10.00%) | 14,661 |
| − sNII < ₹10L | 27,71,056 (5.00%) | 7,330 |
| Retail Shares Offered | 1,93,97,394 (35.00%) | 7,18,422 |
| Total Shares Offered | 5,54,21,123 (100.00%) |
Sai Life Sciences IPO raises ₹912.79 crore from anchor investors. Sai Life Sciences IPO Anchor bid date is December 10, 2024. Sai Life Sciences IPO Anchor Investors list
| Bid Date | December 10, 2024 |
| Shares Offered | 1,66,26,336 |
| Anchor Portion Size (In Cr.) | 912.79 |
| Anchor lock-in period end date for 50% shares (30 Days) | January 14, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | March 15, 2025 |
Sai Life Sciences IPO opens on December 11, 2024, and closes on December 13, 2024.
| IPO Open Date | Wed, Dec 11, 2024 |
| IPO Close Date | Fri, Dec 13, 2024 |
| Tentative Allotment | Mon, Dec 16, 2024 |
| Initiation of Refunds | Tue, Dec 17, 2024 |
| Credit of Shares to Demat | Tue, Dec 17, 2024 |
| Tentative Listing Date | Wed, Dec 18, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on Fri, Dec 13, 2024 |
Investors can bid for a minimum of 27 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 27 | ₹14,823 |
| Retail (Max) | 13 | 351 | ₹1,92,699 |
| S-HNI (Min) | 14 | 378 | ₹2,07,522 |
| S-HNI (Max) | 67 | 1,809 | ₹9,93,141 |
| B-HNI (Min) | 68 | 1,836 | ₹10,07,964 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.
In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023.The services were offered across countries such as the US, the UK, Europe, and Japan.
The company's business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.
The company has the following service offerings.
As of September 30, 2024, the company had 2,353 scientific staff, with the majority of the scientific team holding advanced degrees, including 302 Ph. D.s and 1,475 master’s degrees.
As of September 30, 2024, the company had 3135 employees with capabilities across the CRDMO value chain.
Competitive Strength:
Sai Life Sciences Limited's revenue increased by 20% and profit after tax (PAT) rose by 729% between the financial year ending with March 31, 2024 and March 31, 2023.
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 2,476.78 | 2,275.14 | 2,186.65 | 2,164.23 |
| Total Income | 693.35 | 1,494.27 | 1,245.11 | 897.74 |
| Profit After Tax | 28.01 | 82.81 | 9.99 | 6.23 |
| Net Worth | 1,044.75 | 974.34 | 887.29 | 877.76 |
| Reserves and Surplus | 1,025.44 | 953.99 | 867.43 | 859.17 |
| Total Borrowing | 764.49 | 710.16 | 699.23 | 751.32 |
| Amount in ₹ Crore | ||||
The market capitalization of Sai Life Sciences IPO is ₹11418.63 Cr.
KPI as of Sun, Mar 31, 2024.
| KPI | Values |
|---|---|
| ROE | 11.79% |
| ROCE | 15.96% |
| RoNW | 8.13% |
| PAT Margin | 5.65% |
| Price to Book Value | 10.18 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 4.34 | 2.69 |
| P/E (x) | 126.42 | 203.82 |
[Dilip Davda] The company is innovation focused CRDMO, NCE, CRO, and CMC entity, and a global player for healthcare related products development serving over 25 world’s leading pharma companies. It marked steady growth in its top lines, but the sudden boost in bottom lines for FY24 raises eyebrows. Based on FY25 annualized earnings, the issue appears aggressively priced. Well-informed/cash surplus/risk seekers may park moderate funds for long term. Read detail review...
| Listing Date | December 18, 2024 |
| BSE Script Code | 544306 |
| NSE Symbol | SAILIFE |
| ISIN | INE570L01029 |
| Final Issue Price | ₹549 per share |
| NSE Listing Group | EQ (Rolling) |
| BSE Listing Group | B |
Sai Life Sciences Ltd.
Plot No. DS-7, IKP Knowledge Park
Turkapally Village, Shameerpet Mandal,
Malkajgiri District, Hyderabad-500078
Hyderabad, Telangana
Phone: +9140 6815 6000
Email: investors@sailife.com
Website: https://www.sailife.com/
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: sailifesciences.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
Sai Life Sciences IPO is a main-board IPO of 5,54,21,123 equity shares of the face value of ₹1 aggregating up to ₹3,042.62 Crores. The issue is priced at ₹549 per share. The minimum order quantity is 27.
The IPO opens on December 11, 2024, and closes on December 13, 2024.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Sai Life Sciences IPO using UPI as a payment gateway. Zerodha customers can apply in Sai Life Sciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Sai Life Sciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Sai Life Sciences IPO opens on December 11, 2024 and closes on December 13, 2024.
Sai Life Sciences IPO lot size is 27, and the minimum amount required for application is ₹14,823.
You can apply in Sai Life Sciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Sai Life Sciences IPO will be done on Monday, December 16, 2024, and the allotted shares will be credited to your demat account by Tuesday, December 17, 2024. Check the Sai Life Sciences IPO allotment status.
The Sai Life Sciences IPO listing date is on Wednesday, December 18, 2024.
Useful Articles
RHP